EUVIMEDEUVIMED entdecken
Crossref

Infliximab for vascular involvement in Behçet's syndrome

Gulen Hatemi, Nur Beyza Tukek, Sinem Nihal Esatoglu, Yesim Ozguler, Sitki Safa Taflan, Ugur Uygunoglu, Melike Melikoglu, Serdal Ugurlu, Izzet Fresko, Aksel Siva, Zekayi Kutlubay, Sebahattin Yurdakul und 2 weitere

Clinical Immunology · 2023-08 · 253 · 109682

DOI: 10.1016/j.clim.2023.109682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2023-08. Verfasst von Gulen Hatemi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Behçet's Dis…. Hauptthemen laut MEDLINE: Behcet Syndrome. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Vascular involvement is an important cause of morbidity and mortality in patients with Behçet's syndrome (BS). We aimed to survey the efficacy and safety of infliximab (IFX) in BS patients with vascular involvement followed in a dedicated tertiary center. METHODS: Charts of all BS patients who used IFX for vascular involvement between 2004 and 2022 were reviewed. Primary endpoint was remission at Month 6, defined as lack of new clinical symptoms and findings associated with vascular lesion, lack of worsening of the primary vascular lesion and a new vascular lesion on imaging, and CRP < 10 mg/L. Relapse was defined as development of a new vascular lesion or recurrence of the preexisting vascular lesion. RESULTS: Among the 127 patients (102 men, mean age at IFX initiation: 35.8 ± 9.0 years) treated with IFX, 110 (87%) had received IFX for remission induction and 87 of these (79%) were already on immunosuppressives when the vascular lesion requiring IFX developed. The remission rate was 73% (93/127) at Month 6 and 63% (80/127) at Month 12. Seventeen patients experienced relapses. Remission rates were better among patients with pulmonary artery involvement and venous thrombosis compared to patients with non-pulmonary artery involvement and venous ulcers. Fourteen patients had adverse events leading to IFX discontinuation and 4 had died due to lung adenocarcinoma, sepsis, and pulmonary hypertension-related right heart failure due to pulmonary artery thrombosis (n = 2). CONCLUSION: Infliximab seems to be effective in majority of BS patients with vascular involvement, even in those who are refractory to immunosuppressives and glucocorticoids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Behcet SyndromeMaleHumansInfliximabNeoplasm Recurrence, LocalImmunosuppressive AgentsPulmonary ArteryTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

AneurysmBehçet's syndromeInfliximabThrombosisTumor necrosis factor inhibitorsVascular

Substanzen

InfliximabImmunosuppressive Agents

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Behçet's Disease Research Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Behçet's Disease Research Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Department of Neurology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Behçet's Disease Research Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Department of Dermatology, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey.

Zitieren

APA

Hatemi, G., Tukek, N. B., Esatoglu, S. N., Ozguler, Y., Taflan, S. S., Uygunoglu, U., Melikoglu, M., Ugurlu, S., Fresko, I., Siva, A., Kutlubay, Z., Yurdakul, S., Yazici, H., & Hamuryudan, V. (2023). Infliximab for vascular involvement in Behçet's syndrome. Clinical Immunology, 253, 109682. https://doi.org/10.1016/j.clim.2023.109682

Vancouver

Hatemi G, Tukek NB, Esatoglu SN, Ozguler Y, Taflan SS, Uygunoglu U, et al. Infliximab for vascular involvement in Behçet's syndrome. Clinical Immunology. 2023;253:109682. doi:10.1016/j.clim.2023.109682

BibTeX
@article{Hatemi2023,
  author = {Hatemi, Gulen and Tukek, Nur Beyza and Esatoglu, Sinem Nihal and Ozguler, Yesim and Taflan, Sitki Safa and Uygunoglu, Ugur and Melikoglu, Melike and Ugurlu, Serdal and Fresko, Izzet and Siva, Aksel and Kutlubay, Zekayi and Yurdakul, Sebahattin and Yazici, Hasan and Hamuryudan, Vedat},
  title = {Infliximab for vascular involvement in Behçet's syndrome},
  journal = {Clinical Immunology},
  year = {2023},
  volume = {253},
  pages = {109682},
  doi = {10.1016/j.clim.2023.109682}
}
Kostenlos starten →